EGFR Exon 20 Insertion NSCLC: Amivantamab Bispecific Antibody

CHRYSALIS Phase I Trial Results

EGFR exon 20 insertion mutations represent a challenging therapeutic target in NSCLC, with limited efficacy from first and third-generation EGFR inhibitors. Amivantamab, a bispecific antibody targeting both EGFR and MET, provides a novel therapeutic approach.

Key Efficacy Results

Objective Response Rate: 40% in platinum-pretreated patients

• Includes complete response in selected patients
• Median response duration: 11.1 months
• Median PFS: 8.3 months

Safety Profile

Infusion Reactions: ~66% of patients, primarily manageable with premedication

Dermatologic Toxicities: Paronychia, rash; manageable with skin care protocols

No dose-limiting toxicities identified.

Clinical Mechanism

Amivantamab's bispecific targeting of EGFR and MET receptors overcomes resistance mechanisms from prior EGFR-directed therapies. Approved in multiple countries as standard therapy for exon 20 insertion NSCLC.

Data Source

CHRYSALIS Phase I Trial, Journal of Clinical Oncology

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4